Challenges and perspectives in the treatment of patients with haemophilia in Brasil
Open Access
- 1 October 2018
- journal article
- letter
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 64 (10) , 872-875
Abstract
Haemophilia affects more than 184,000 people worldwide.1 Despite increasing advances, it is still associated with a high prevalence of disabilities, posing an economic burden to individuals and health systems.2 Over the last decades, significant therapeutic improvements have been achieved, including advances in blood safety, prophylaxis with coagulation factor concentrates (CFC), treatment with inhibitors of coagulation factors, orthopedic surgeries to correct limbs deformities and long-acting CFC.2,3 It is anticipated that new compounds which could be applied subcutaneously and gene therapy will be of benefit to patients with hemophilia (PWH) in the future.4Keywords
This publication has 5 references indexed in Scilit:
- Novel approaches to hemophilia therapy: successes and challengesBlood, 2017
- 2017 Clinical trials update: Innovations in hemophilia therapyAmerican Journal of Hematology, 2016
- Young adults with hemophilia in the U.S.: demographics, comorbidities, and health statusAmerican Journal of Hematology, 2015
- Health care expenditures for Medicaid‐covered males with haemophilia in the United States, 2008Haemophilia, 2011
- Genetic diagnosis of haemophilia and other inherited bleeding disordersHaemophilia, 2006